BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

Core Insights - BioRestorative Therapies, Inc. has completed patient enrollment in its Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease (cLDD) [1][3][8] Company Overview - BioRestorative is focused on stem cell-based therapies and products, with BRTX-100 as its lead clinical candidate, designed for low-oxygen, low-nutrient disc environments [2][11] - The company operates in the regenerative medicine sector, developing therapeutic products primarily using adult stem cells [12] Clinical Trial Details - The Phase 2 trial has enrolled 99 patients across 15 U.S. clinical sites, believed to be the largest Phase 2 cell-therapy trial for cLDD under FDA IND application [3][5] - The trial employs a randomized, double-blind, sham-controlled design, considered the gold standard for clinical studies in spine interventions [4][9] - Primary safety endpoints include the frequency and severity of adverse events, while efficacy endpoints focus on a greater than 30% improvement in function and pain reduction at week 52 [5][10] Enrollment and Milestones - Enrollment completion is seen as a significant operational and clinical milestone, reflecting years of disciplined execution and scientific focus [8][7] - Approximately 40% of total enrollment occurred in the last six months, indicating increased site productivity and investigator engagement [7] Future Prospects - The completion of enrollment positions the program favorably for regulatory dialogue and advancement towards Phase 3 development and potential Biologics License Application (BLA) submission [8][9]